This is because, similar to the cancer of breast, lung and ovary, TF is also expressed at high percentages in many other human solid cancers [15], for instance, 95% in primary melanoma and 100% in metastatic melanoma, 53%-90% in pancreatic cancer, 57%-100% in colorectal cancer, 63%-100% in hepatocellular carcinoma, 60%-78% in primary and metastatic prostate cancer and 47%-75% in glioma. Here, TF is linked to colorectal cancer.